SPY366.02+3.96 1.09%
DIA299.95+3.33 1.12%
IXIC12,312.59+113.86 0.93%

Goldman Sachs Initiates Coverage On Foghorn Therapeutics with Buy Rating, Announces Price Target of $27

Goldman Sachs analyst Paul Choi initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy rating and announces Price Target of $27.

· 11/17/2020 06:34
Goldman Sachs analyst Paul Choi initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy rating and announces Price Target of $27.